180 related articles for article (PubMed ID: 34504204)
1. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
Kim M; Choi HY; Woo JW; Chung YR; Park SY
Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
[TBL] [Abstract][Full Text] [Related]
2. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
4. Immune Escape in Breast Cancer During
Gil Del Alcazar CR; Huh SJ; Ekram MB; Trinh A; Liu LL; Beca F; Zi X; Kwak M; Bergholtz H; Su Y; Ding L; Russnes HG; Richardson AL; Babski K; Min Hui Kim E; McDonnell CH; Wagner J; Rowberry R; Freeman GJ; Dillon D; Sorlie T; Coussens LM; Garber JE; Fan R; Bobolis K; Allred DC; Jeong J; Park SY; Michor F; Polyak K
Cancer Discov; 2017 Oct; 7(10):1098-1115. PubMed ID: 28652380
[TBL] [Abstract][Full Text] [Related]
5. Functional CD3
Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
[TBL] [Abstract][Full Text] [Related]
7. The immune microenvironment of breast ductal carcinoma in situ.
Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
[TBL] [Abstract][Full Text] [Related]
8. Relationship of the Breast Ductal Carcinoma
Hendry S; Pang JB; Byrne DJ; Lakhani SR; Cummings MC; Campbell IG; Mann GB; Gorringe KL; Fox SB
Clin Cancer Res; 2017 Sep; 23(17):5210-5217. PubMed ID: 28611201
[No Abstract] [Full Text] [Related]
9. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
10. Higher densities of tumour-infiltrating lymphocytes and CD4
Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
12. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
[TBL] [Abstract][Full Text] [Related]
14. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
[TBL] [Abstract][Full Text] [Related]
15. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.
Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB
BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211
[TBL] [Abstract][Full Text] [Related]
16. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
[TBL] [Abstract][Full Text] [Related]
17. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.
Mulligan AM; Raitman I; Feeley L; Pinnaduwage D; Nguyen LT; O'Malley FP; Ohashi PS; Andrulis IL
Clin Cancer Res; 2013 Jan; 19(2):336-46. PubMed ID: 23213058
[TBL] [Abstract][Full Text] [Related]
18. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.
Datta D; Flaxenburg JA; Laxmanan S; Geehan C; Grimm M; Waaga-Gasser AM; Briscoe DM; Pal S
Cancer Res; 2006 Oct; 66(19):9509-18. PubMed ID: 17018607
[TBL] [Abstract][Full Text] [Related]
19. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
20. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]